CXCR4 and breast cancer: Studies blocking the vital chemotactic function of SDF-1 using CXCR4 inhibitor AMD-3100 reported increased effectiveness of a vascular-disrupting agent, combretastatin, in a mouse model of breast cancer, presumably by preventing TIE2-expressing macrophages from being recruited to tumors [101].